Company Profile
Krystal Biotech Stock Price, News & Analysis
- Ticker:
- KRYS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
351.82 USD (+4.96%)
Close
Last updated: July 27, 2026
8.64B USD
Market cap
Why the stock is moving
Following the latest company update, “Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026”, KRYS closed up 2.35% at $335.19 on Jul 24, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Business overview
Krystal Biotech is a gene-therapy company focused on dermatology and other rare diseases, with a commercial franchise in epidermolysis bullosa.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Krystal sits in specialty gene therapy.
Business Model Characteristics
The company combines commercial gene-therapy revenue with pipeline expansion into additional skin and respiratory applications.
Position Within the Biotechnology Landscape
Krystal occupies a premium niche because it has turned gene therapy into a real commercial business.
Future catalysts
Krystal's catalysts are Vyjuvek commercial growth and any follow-on dermatology or gene-therapy step that broadens the franchise. The stock will care about whether the first approval keeps turning into a durable commercial base.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
- 03
- 04
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
CAPR · Source: Capricor Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Krystal Biotech (KRYS)?
Krystal Biotech (KRYS) most recently closed at 351.82 USD, a +4.96% move versus the previous session.
What is the market cap of Krystal Biotech (KRYS)?
Krystal Biotech currently has a market capitalization of 8.64B USD on BioPharmSignal.
What does Krystal Biotech do?
Krystal Biotech is a gene-therapy company focused on dermatology and other rare diseases, with a commercial franchise in epidermolysis bullosa.
On which exchange is KRYS stock listed?
Krystal Biotech (KRYS) is associated with NASDAQ, United States, Biopharma.
What is Krystal?
Krystal's catalysts are Vyjuvek commercial growth and any follow-on dermatology or gene-therapy step that broadens the franchise.
Which conditions is Krystal Biotech targeting with Krystal?
Krystal Biotech is associated with rare disease, dermatology based on its company overview and current catalyst commentary.
How does Krystal Biotech describe recent progress with Krystal?
Krystal's catalysts are Vyjuvek commercial growth and any follow-on dermatology or gene-therapy step that broadens the franchise.
What is Biotech?
Krystal Biotech is a gene-therapy company focused on dermatology and other rare diseases, with a commercial franchise in epidermolysis bullosa.